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Background: High ferritin levels are associated with insulin resistance (IR) and liver steatosis, both thought of as emerging cardiovascular (CV) 
risk factors. The association between ferritin and CV disease is poorly documented in cardiometabolic states with higher CV risk, such as diabetes 
and metabolic syndrome. We therefore characterized a cohort of type 2 diabetes mellitus (T2DM) males according to ferritin levels and prevalent 
macroangiopathy.
Methods: Overall macroangiopathy, peripheral and/or coronary artery disease status was obtained from 424 consecutive T2DM males, who were 
divided according to ferritin quartiles (Q): QI-III (normal ferritin (NFer), n=318, mean (1 SD) ferritin: 133 (72) ng/ml) and QIV patients (high ferritin 
(HFer), n=106, ferritin: 480 (228) ng/ml).
Results: Age, age at diabetes diagnosis, smoking, ethanol intake, body mass index, waist circumference, blood pressure and presence of metabolic 
syndrome did not differ between groups. Insulin resistance (IR) index (HOMA) and liver steatosis prevalence were higher in HFer: 2.17 vs. 1.89 and 
78 vs. 64% in NFer patients (p 0.0345 and 0.0059, respectively). Liver enzymes (AST, ALT and GGT) were significantly higher in HFer, by 33, 42 and 
72%, respectively (all p<0.0002), suggesting higher prevalence of steatohepatitis. HbA1c, LDL-C, HDL-C, triglycerides and uric acid were not different 
between groups, nor were hsCRP and albuminuria. Yet, macroangiopathy prevalence was unexpectedly much lower in patients with high ferritin: 25 
vs. 43% (overal macroangiopathy); 7 vs. 16% (peripheral artery disease); and 16 vs. 31% (coronary artery disease) (p 0.0009, 0.0140 and 0.0035 
vs. NFer patients).
Conclusions: : Our results demonstrate that diabetic males with high ferritin levels exhibit a markedly decreased macroangiopathy prevalence, 
despite more severe insulin resistance and higher markers of steatohepatitis. High ferritin levels and/or steatosis may thus paradoxically confer a 
lowered cardiovascular risk in type 2 diabetes.
